Sacks Greg D, Wojtalik Luke, Kaslow Sarah R, Penfield Christina A, Kang Stella K, Hewitt D B, Javed Ammar A, Wolfgang Christopher L, Braithwaite R S
Department of Surgery, New York University Grossman School of Medicine and NYU-Langone Health, New York, NY, USA; Department of Obstetrics and Gynecology, New York University Grossman School of Medicine and NYU-Langone Health, New York, NY, USA.
Department of Surgery, New York University Grossman School of Medicine and NYU-Langone Health, New York, NY, USA.
HPB (Oxford). 2025 Jan;27(1):94-101. doi: 10.1016/j.hpb.2024.10.006. Epub 2024 Oct 18.
IPMN consensus guidelines make implicit judgments on what cancer risk level should prompt surgery. We used decision modeling to estimate this cancer risk threshold (CRT) for BD-IPMN patients.
We created a decision model to compare quality-adjusted life years (QALYs) following surgery or surveillance for BD-IPMNs. We simulated treatment decisions for hypothetical patients, varying age, comorbidities and lesion location (pancreatic head/tail). The base case was a 60-year-old patient with mild comorbidities and pancreatic head IPMN. Probabilities, life expectancies, and utilities were incorporated from literature/public datasets. CRT was defined as the level of cancer risk at which the expected value of QALYs for surgery first exceeded that of surveillance.
In the base case, surgery was preferred over surveillance, yielding 21.90 vs. 21.88 QALYs. The optimal CRT for a BD-IPMN patient depended on age, comorbidities, and location. CRT in the base case was 20 % and 3 % for an IPMN in the head and tail of the pancreas, respectively. Other drivers of preferred treatment were age and likelihood of postoperative mortality.
For BD-IPMNs, the optimal CRT varies depending on patient age and risk of surgical complications. Personalized risk threshold values could guide treatment decisions and inform future treatment consensus guidelines.
IPMN共识指南对何种癌症风险水平应促使进行手术做出了隐含判断。我们使用决策模型来估计BD-IPMN患者的这种癌症风险阈值(CRT)。
我们创建了一个决策模型,以比较BD-IPMN患者手术后或进行监测后的质量调整生命年(QALY)。我们模拟了假设患者的治疗决策,这些患者的年龄、合并症和病变位置(胰头/胰尾)各不相同。基础病例是一名60岁、合并症较轻且患有胰头IPMN的患者。概率、预期寿命和效用值来自文献/公共数据集。CRT被定义为手术的QALY期望值首次超过监测的QALY期望值时的癌症风险水平。
在基础病例中,手术优于监测,QALY分别为21.90和21.88。BD-IPMN患者的最佳CRT取决于年龄、合并症和位置。基础病例中,胰头和胰尾IPMN的CRT分别为20%和3%。首选治疗的其他驱动因素是年龄和术后死亡率。
对于BD-IPMN,最佳CRT因患者年龄和手术并发症风险而异。个性化的风险阈值可以指导治疗决策,并为未来的治疗共识指南提供参考。